1. Cell Biology

Metabolic flexibility via mitochondrial BCAA carrier SLC25A44 is required for optimal fever

  1. Takeshi Yoneshiro
  2. Naoya Kataoka
  3. Jacquelyn M Walejko
  4. Kenji Ikeda
  5. Zachary Brown
  6. Momoko Yoneshiro
  7. Scott B Crown
  8. Tsuyoshi Osawa
  9. Juro Sakai
  10. Robert W McGarrah
  11. Phillip J White
  12. Kazuhiro Nakamura
  13. Shingo Kajimura  Is a corresponding author
  1. University of Tokyo, Japan
  2. Nagoya University Graduate School of Medicine, Japan
  3. Duke University School of Medicine, United States
  4. Tokyo Medical and Dental University, Japan
  5. University of California, San Francisco, United States
  6. The University of Tokyo, Japan
  7. Beth Israel Deaconess Medical Center, United States
https://doi.org/10.7554/eLife.66865
Share this article
Cite this article
  1. Takeshi Yoneshiro
  2. Naoya Kataoka
  3. Jacquelyn M Walejko
  4. Kenji Ikeda
  5. Zachary Brown
  6. Momoko Yoneshiro
  7. Scott B Crown
  8. Tsuyoshi Osawa
  9. Juro Sakai
  10. Robert W McGarrah
  11. Phillip J White
  12. Kazuhiro Nakamura
  13. Shingo Kajimura
(2021)
Metabolic flexibility via mitochondrial BCAA carrier SLC25A44 is required for optimal fever
eLife 10:e66865.
https://doi.org/10.7554/eLife.66865
  2. Download BibTeX
  3. Download .RIS

Abstract

Importing necessary metabolites into the mitochondrial matrix is a crucial step of fuel choice during stress adaptation. Branched chain-amino acids (BCAA) are essential amino acids needed for anabolic processes, but they are also imported into the mitochondria for catabolic reactions. What controls the distinct subcellular BCAA utilization during stress adaptation is insufficiently understood. The present study reports the role of SLC25A44, a recently identified mitochondrial BCAA carrier (MBC), in the regulation of mitochondrial BCAA catabolism and adaptive response to fever in rodents. We found that mitochondrial BCAA oxidation in brown adipose tissue (BAT) is significantly enhanced during fever in response to the pyrogenic mediator prostaglandin E2 (PGE2) and psychological stress in mice and rats. Genetic deletion of MBC in a BAT-specific manner blunts mitochondrial BCAA oxidation and non-shivering thermogenesis following intracerebroventricular PGE2 administration. At a cellular level, MBC is required for mitochondrial BCAA deamination as well as the synthesis of mitochondrial amino acids and TCA intermediates. Together, these results illuminate the role of MBC as a determinant of metabolic flexibility to mitochondrial BCAA catabolism and optimal febrile responses. This study also offers an opportunity to control fever by rewiring the subcellular BCAA fate.

Data availability

All data generated or analyzed during this study are included in the manuscript as source data files.

The following previously published data sets were used

Article and author information

Author details

  1. Takeshi Yoneshiro

    Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan
    Competing interests
    The authors declare that no competing interests exist.

  2. Naoya Kataoka

    Department of Integrative Physiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Competing interests
    The authors declare that no competing interests exist.

  3. Jacquelyn M Walejko

    Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, United States
    Competing interests
    The authors declare that no competing interests exist.

  4. Kenji Ikeda

    Department of Molecular Endocrinology and Metabolism, Tokyo Medical and Dental University, Tokyo, Japan
    Competing interests
    The authors declare that no competing interests exist.

  5. Zachary Brown

    Diabetes Center, University of California, San Francisco, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.

  6. Momoko Yoneshiro

    Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan
    Competing interests
    The authors declare that no competing interests exist.

  7. Scott B Crown

    Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, United States
    Competing interests
    The authors declare that no competing interests exist.

  8. Tsuyoshi Osawa

    Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan
    Competing interests
    The authors declare that no competing interests exist.

  9. Juro Sakai

    Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan
    Competing interests
    The authors declare that no competing interests exist.

  10. Robert W McGarrah

    Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, United States
    Competing interests
    The authors declare that no competing interests exist.

  11. Phillip J White

    Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, United States
    Competing interests
    The authors declare that no competing interests exist.

  12. Kazuhiro Nakamura

    Department of Integrative Physiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Competing interests
    The authors declare that no competing interests exist.

  13. Shingo Kajimura

    Endocrinology, Diabetes & Metabolism, Beth Israel Deaconess Medical Center, Boston, United States
    For correspondence
    skajimur@bidmc.harvard.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0672-5910

Funding

National Institute of Diabetes and Digestive and Kidney Diseases (DK097441)

  • Shingo Kajimura

MEXT KAKENHI (15H05932,15K21744)

  • Naoya Kataoka

MEXT KAKENHI (20H03418)

  • Naoya Kataoka

MEXT KAKENHI (19K06954)

  • Kazuhiro Nakamura

AMED (JP21gm5010002s0305)

  • Kazuhiro Nakamura

JST Moonshot R&D (JPMJMS2023)

  • Kazuhiro Nakamura

National Institute of Diabetes and Digestive and Kidney Diseases (DK126160)

  • Shingo Kajimura

National Institute of Diabetes and Digestive and Kidney Diseases (DK125281)

  • Shingo Kajimura

National Institute of Diabetes and Digestive and Kidney Diseases (DK127575)

  • Shingo Kajimura

The Edward Mallinckrodt, Jr. Foundation

  • Shingo Kajimura

National Heart and Lung Institute (5K08HL13527)

  • Robert W McGarrah

National Heart and Lung Institute (F32HL137398)

  • Scott B Crown

American Diabetes Association (1-16-INI-17)

  • Phillip J White

MEXT KAKENHI (19K06954)

  • Kazuhiro Nakamura

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All the animal experiments were performed following the guidelines by the UCSF Institutional Animal Care and Use Committee or by the Nagoya University Animal Experiment Committee. The protocols were approved by the committees by the Committee on the Ethics of Animal Experiments of UCSF (AN165833) and Nagoya University. All surgery was performed under anesthesia, and every effort was made to minimize suffering.

Copyright

© 2021, Yoneshiro et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,971
    views
  • 471
    downloads
  • 26
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Takeshi Yoneshiro
  2. Naoya Kataoka
  3. Jacquelyn M Walejko
  4. Kenji Ikeda
  5. Zachary Brown
  6. Momoko Yoneshiro
  7. Scott B Crown
  8. Tsuyoshi Osawa
  9. Juro Sakai
  10. Robert W McGarrah
  11. Phillip J White
  12. Kazuhiro Nakamura
  13. Shingo Kajimura
(2021)
Metabolic flexibility via mitochondrial BCAA carrier SLC25A44 is required for optimal fever
eLife 10:e66865.
https://doi.org/10.7554/eLife.66865

Share this article

https://doi.org/10.7554/eLife.66865

Categories and tags

Research organism

Further reading

    1. Cell Biology
    2. Neuroscience

    Aβ-driven nuclear pore complex dysfunction alters activation of necroptosis proteins in a mouse model of Alzheimer’s disease

    Vibhavari Aysha Bansal, Jia Min Tan ... Toh Hean Ch'ng
    Research Article

    The emergence of Aβ pathology is one of the hallmarks of Alzheimer’s disease (AD), but the mechanisms and impact of Aβ in progression of the disease is unclear. The nuclear pore complex (NPC) is a multi-protein assembly in mammalian cells that regulates movement of macromolecules across the nuclear envelope; its function is shown to undergo age-dependent decline during normal aging and is also impaired in multiple neurodegenerative disorders. Yet not much is known about the impact of Aβ on NPC function in neurons. Here, we examined NPC and nucleoporin (NUP) distribution and nucleocytoplasmic transport using a mouse model of AD (AppNL-G-F/NL-G-F) that expresses Aβ in young animals. Our studies revealed that a time-dependent accumulation of intracellular Aβ corresponded with a reduction of NPCs and NUPs in the nuclear envelope which resulted in the degradation of the permeability barrier and inefficient segregation of nucleocytoplasmic proteins, and active transport. As a result of the NPC dysfunction App KI neurons become more vulnerable to inflammation-induced necroptosis – a programmed cell death pathway where the core components are activated via phosphorylation through nucleocytoplasmic shutting. Collectively, our data implicates Aβ in progressive impairment of nuclear pore function and further confirms that the protein complex is vulnerable to disruption in various neurodegenerative diseases and is a potential therapeutic target.

    1. Cell Biology

    Oxidized low-density lipoprotein potentiates angiotensin II-induced Gq activation through the AT1-LOX1 receptor complex

    Jittoku Ihara, Yibin Huang ... Koichi Yamamoto
    Research Article

    Chronic kidney disease (CKD) and atherosclerotic heart disease, frequently associated with dyslipidemia and hypertension, represent significant health concerns. We investigated the interplay among these conditions, focusing on the role of oxidized low-density lipoprotein (oxLDL) and angiotensin II (Ang II) in renal injury via G protein αq subunit (Gq) signaling. We hypothesized that oxLDL enhances Ang II-induced Gq signaling via the AT1 (Ang II type 1 receptor)-LOX1 (lectin-like oxLDL receptor) complex. Based on CHO and renal cell model experiments, oxLDL alone did not activate Gq signaling. However, when combined with Ang II, it significantly potentiated Gq-mediated inositol phosphate 1 production and calcium influx in cells expressing both LOX-1 and AT1 but not in AT1-expressing cells. This suggests a critical synergistic interaction between oxLDL and Ang II in the AT1-LOX1 complex. Conformational studies using AT1 biosensors have indicated a unique receptor conformational change due to the oxLDL-Ang II combination. In vivo, wild-type mice fed a high-fat diet with Ang II infusion presented exacerbated renal dysfunction, whereas LOX-1 knockout mice did not, underscoring the pathophysiological relevance of the AT1-LOX1 interaction in renal damage. These findings highlight a novel mechanism of renal dysfunction in CKD driven by dyslipidemia and hypertension and suggest the therapeutic potential of AT1-LOX1 receptor complex in patients with these comorbidities.

    1. Cell Biology

    ORMDL3 restrains type I interferon signaling and anti-tumor immunity by promoting RIG-I degradation

    Qi Zeng, Chen Yao ... Shuai Chen
    Research Article

    Mounting evidence has demonstrated the genetic association of ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3) gene polymorphisms with bronchial asthma and a diverse set of inflammatory disorders. However, its role in type I interferon (type I IFN) signaling remains poorly defined. Herein, we report that ORMDL3 is a negative modulator of the type I IFN signaling by interacting with mitochondrial antiviral signaling protein (MAVS) and subsequently promoting the proteasome-mediated degradation of retinoic acid-inducible gene I (RIG-I). Immunoprecipitation coupled with mass spectrometry (IP-MS) assays uncovered that ORMDL3 binds to ubiquitin-specific protease 10 (USP10), which forms a complex with and stabilizes RIG-I through decreasing its K48-linked ubiquitination. ORMDL3 thus disrupts the interaction between USP10 and RIG-I, thereby promoting RIG-I degradation. Additionally, subcutaneous syngeneic tumor models in C57BL/6 mice revealed that inhibition of ORMDL3 enhances anti-tumor efficacy by augmenting the proportion of cytotoxic CD8 positive T cells and IFN production in the tumor microenvironment (TME). Collectively, our findings reveal the pivotal roles of ORMDL3 in maintaining antiviral innate immune responses and anti-tumor immunity.